Overview

Sofosbuvir Plus Ribavirin in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection

Status:
Completed

Trial end date:
2014-02-01

Target enrollment:

Participant gender:

Summary

This study is to evaluate the safety, tolerability, and antiviral activity of sofosbuvir (SOF) with ribavirin (RBV) in Egyptian adults with chronic genotype 4 hepatitis C virus (HCV) infection.

Phase:

Phase 2

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Ribavirin
Sofosbuvir